New link found between MS treatment and vitamin D

July 30, 2012, University of Tasmania

(Medical Xpress) -- A new study by researchers at the Menzies Research Institute Tasmania (Menzies) suggests that one of the main treatments for multiple sclerosis (MS) may also increase the amount of vitamin D patients receive from sun exposure.

More people suffer with per capita in Tasmania than in any other state in Australia. There is currently no cure, but treatments are available to ease some of the symptoms.

This observational study published in the prestigious journal Neurology found that patients taking one of the most common treatments for MS, interferon-beta, had higher levels than those not on this or those using other forms of treatment for MS.

Around 60 per cent of with the relapsing-remitting form of MS are treated with interferon-beta. It is derived from a naturally-occurring component of the and has been found to reduce the frequency of and other specific symptoms of MS.

Despite being a front-line treatment in MS, how interferon-beta actually works in MS is unclear, though it is thought to act by affecting the immune system.

The study used data from the MS Longitudinal Study, from 2002-2005, and this analysis used data from 178 persons with MS living in southern Tasmania.

Menzies researchers Dr. Niall Stewart and Dr. Steve Simpson, Jr. were co-first authors on the paper. Dr. Simpson says the findings suggest that part of the therapeutic effects of interferon-beta on relapse in MS may be through its effects on vitamin D, since vitamin D has the ability to reduce inflammatory pathways in the immune system.

“Not only did we find that persons taking interferon-beta had higher vitamin D levels than those not taking it, we also found that this increase in vitamin D was due to an enhancement of the association between sun and vitamin D, with persons on interferon-beta having nearly three-times as much vitamin D from similar amounts of to those not taking interferon-beta,” Dr. Simpson said.

“We have previously shown persons with MS with higher vitamin D levels had lower numbers of relapses. In this analysis, however, we found that vitamin D was only associated with reduced risk of relapse among those using interferon-beta.

“Interestingly, the reciprocal was also true, with interferon-beta only associated with reduced risk of relapse among those with higher levels of vitamin D,” Dr. Simpson said.

Senior author, Professor Bruce Taylor, says the new findings have the potential to markedly affect clinical practice in the treatment of MS, but cautions that more research is required.

“This study adds to the growing body of research into MS, but before we can apply these findings to MS treatment practice, clinical trials must be done to prove these associations. Menzies is planning to undertake such a trial in the future,” Professor Taylor said.

“This study does provide further support for persons with MS to periodically have their vitamin D measured, particularly in winter, and if they are deficient, to seek the advice of their physician as to whether supplementation is appropriate for them.”

The MS was funded by the National Health & Medical Research Council, the Trish Foundation and the University of Tasmania.

Explore further: High-dose vitamin D may not be better than low-dose vitamin D in treating MS

Related Stories

High-dose vitamin D may not be better than low-dose vitamin D in treating MS

October 24, 2011
Low vitamin D levels are associated with an increased risk of developing multiple sclerosis (MS), but the first randomized, controlled trial using high-dose vitamin D in MS did not find any added benefit over and above ongoing ...

Breakthrough in the search for new treatments for multiple sclerosis

June 21, 2011
Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) -- a chronic inflammatory disease of the central nervous ...

Poor bone health may start early in people with multiple sclerosis

July 11, 2011
Osteoporosis and low bone density are common in people in the early stages of multiple sclerosis (MS), according to a new study published in the July 12, 2011, print issue of Neurology.

Study: MS drugs help, but come at high cost

July 20, 2011
A new study examining the cost-effectiveness of drugs to treat multiple sclerosis (MS) in the United States finds that the health gains from these drugs come at a very high cost compared to basic therapy to control the symptoms ...

Recommended for you

Therapeutic antibodies protected nerve–muscle connections in a mouse model of Lou Gehrig's disease

February 20, 2018
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, causes lethal respiratory paralysis within several years of diagnosis. There are no effective treatments to slow or halt this devastating disease. Mouse ...

Brain immune system is key to recovery from motor neuron degeneration

February 20, 2018
The selective demise of motor neurons is the hallmark of Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS). Yet neurologists have suspected there are other types of brain cells involved in the progression ...

Brain liquefaction after stroke is toxic to surviving brain: study

February 20, 2018
Scientists have known for years that the brain liquefies after a stroke. If cut off from blood and oxygen for a long enough period, a portion of the brain will die, slowly morphing from a hard, rubbery substance into liquid ...

Brain aging may begin earlier than expected

February 20, 2018
Physicists have devised a new method of investigating brain function, opening a new frontier in the diagnoses of neurodegenerative and ageing related diseases.

Every experience that the brain perceives is unique

February 20, 2018
Neuronal activity in the prefrontal cortex represents every experience as "novel." The neurons adapt their activity accordingly, even if the new experience is very similar to a previous one. That is the main finding of a ...

Electrical implant reduces 'invisible' symptoms of man's spinal cord injury

February 19, 2018
An experimental treatment that sends electrical currents through the spinal cord has improved "invisible" yet debilitating side effects for a B.C. man with a spinal cord injury.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.